Abstract Body

Development of effective technologies supporting patient self-care behaviors, real-time monitoring or optimization of treatment regimen is essential for people living with chronic health conditions, such as diabetes, where suboptimal adherence to medication and lifestyle modification can compromise patient outcomes. When people living with diabetes receive basal insulin, as part of their treatment regimen, it is assumed that basal insulin treatment is adapted and personalized. However, only ~25% of those on basal insulin achieve glycemic control, indicating that a significant gap remains. Since basal insulin is a foundational pilar for management of people with diabetes, we believe it is imperative to address the gaps in treatment regimen optimization and improve adherence to basal insulin using effective technologies.

The suggested strategies include the use of digital devices amongst which the connected insulin pen plays a key role. However, at Sanofi we believe that the game-changing determinant for adoption of next-generation pens is user experience. The question we asked ourselves is – what matters most to people with diabetes: Convenience of use? Live data? Device autonomy? Interoperability with digital companions? Fit into existing life and care routines? Or health outcomes?

In this context and as part of its commitment to help people with diabetes, Sanofi will present its connected solutions designed with the intention to support basal insulin management in fitting user expectations and guided by strict user safety standards. We believe such solutions could provide greater convenience for people with diabetes and support improved patient-healthcare provider interaction.